MINIMAL RESIDUAL DISEASE ASSESSED BY NPM1 MUTATION-SPECIFIC RQ-PCR ASSAYS HAS A PROGNOSTIC VALUE IN ACUTE MYELOID LEUKEMIA (AML) AND IS SIGNIFICANTLY DECREASED BY TREATMENT WITH GEMTUZUMAB OZOGAMICIN

被引：0
|
作者：
Lambert, J. [1 ,2 ]
Lambert, J. [1 ,2 ]
Nibourel, O. [3 ]
Pautas, C. [4 ]
Hayette, S. [5 ]
Cayuela, J. M. [6 ]
Terre, C. [7 ]
Dombret, H. [8 ]
Preudhomme, C. [3 ]
Castaigne, S. [9 ]
Renneville, A. [3 ]
机构：
[1] Univ Versailles St Quentin, Hop Versailles, Le Chesnay, France
[2] Hop St Louis, Serv Biostat & Informat Med, Paris, France
[3] CHRU Lille, Lab Hematol, Lille, France
[4] Hop Henri Mondor, Serv Hematol Clin, Creteil, France
[5] CH Lyon Sud, Lab Hematol, Pierre Benite, France
[6] Hop St Louis, Lab Hematol, Paris, France
[7] Ctr Hosp Versailles, Lab Cytogenet, Le Chesnay, France
[8] Hop St Louis, Serv Hematol Adulte, Paris, France
[9] Ctr Hosp Versailles, Serv Hematol & Oncol, Le Chesnay, France
来源：
HAEMATOLOGICA | 2012年 / 97卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0537
引用
收藏
页码：215 / 216
页数：2
相关论文
共 40 条
  • [21] Prognostic impact of early minimal residual disease combined with complete molecular evaluation in acute myeloid leukemia with mutated NPM1: a single center study
    Memoli, Mara
    Genthon, Alexis
    Favale, Fabrizia
    Lapusan, Simona
    Johnson, Natacha
    Adaeva, Rosa
    Deswarte, Caroline
    Battipaglia, Giorgia
    Malard, Florent
    Dulery, Remy
    Brissot, Eolia
    Banet, Anne
    Van de Wyngaert, Zoe
    Mohty, Mohamad
    Delhommeau, Francois
    Legrand, Ollivier
    Hirsch, Pierre
    LEUKEMIA & LYMPHOMA, 2022, 63 (09) : 2171 - 2179
  • [22] Quantitative detection of IDH2 mutation for minimal residual disease monitoring in patients with acute myeloid leukemia and its comparison with mutations in NPM1 gene
    Jeziskova, Ivana
    Razga, Filip
    Toskova, Martina
    Dvorakova, Dana
    Timilsina, Shira
    Mayer, Jiri
    Racil, Zdenek
    LEUKEMIA & LYMPHOMA, 2013, 54 (04) : 867 - 870
  • [23] Postinduction Minimal Residual Disease Predicts Outcome and Benefit From Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia With NPM1 Mutation: A Study by the Acute Leukemia French Association Group
    Balsat, Marie
    Renneville, Aline
    Thomas, Xavier
    de Botton, Stephane
    Caillot, Denis
    Marceau, Alice
    Lemasle, Emilie
    Marolleau, Jean-Pierre
    Nibourel, Olivier
    Berthon, Celine
    Raffoux, Emmanuel
    Pigneux, Arnaud
    Rodriguez, Celine
    Vey, Norbert
    Cayuela, Jean-Michel
    Hayette, Sandrine
    Braun, Thorsten
    Coude, Marie Magdeleine
    Terre, Christine
    Celli-Lebras, Karine
    Dombret, Herve
    Preudhomme, Claude
    Boissel, Nicolas
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (02) : 185 - +
  • [24] Molecular Detection of Minimal Residual Disease Provides the Most Powerful Independent Prognostic Factor Irrespective of Clonal Architecture in Nucleophosmin (NPM1) Mutant Acute Myeloid Leukemia
    Ivey, Adam
    Hills, Robert K.
    Simpson, Michael A.
    Jovanovic, Jelena V.
    Gilkes, Amanda F.
    Patel, Yashma
    Bhudia, Neesa
    Farah, Hassan
    Mason, Joanne
    Wall, Kerry
    Akiki, Susanna
    Solomon, Ellen
    McCaughan, Frank
    Linch, David C.
    Gale, Rosemary E.
    Vyas, Paresh
    Freeman, Sylvie D.
    Russell, Nigel
    Burnett, Alan K.
    Grimwade, David
    BLOOD, 2014, 124 (21)
  • [25] Comparison of Minimal Residual Disease Detection by Multi-Parameter Flow Cytometry and PCR in NPM1-Mutated vs NPM1/FLT3 ITD Mutated Acute Myeloid Leukemia
    Jaso, Jesse Manuel
    Lin, Pei
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2014, 142 (05) : 721 - 722
  • [26] Molecular minimal residual disease negativity and decreased stem cell mobilization potential predict excellent outcome after autologous transplant in NPM1 mutant acute myeloid leukemia
    de Benito, Alvaro de Santiago
    Jeker, Barbara
    Gfeller, Eva
    Porret, Naomi
    Banz, Yara
    Novak, Urban
    Bacher, Ulrike
    Pabst, Thomas
    HAEMATOLOGICA, 2020, 105 (01) : E9 - E12
  • [27] ACUTE MYELOID LEUKEMIA (AML) PATIENTS HARBOURING BOTH, FLT3-ITD AND NPM1 MUTATION, MAY BENEFIT FROM A MINIMAL RESIDUAL DISEASES (MRD) GUIDED TRANSPLANT DECISION
    Schiller, J.
    Praulich, I.
    Hallek, M.
    Kreuzer, K.
    HAEMATOLOGICA, 2013, 98 : 22 - 23
  • [28] Monitoring of minimal residual disease (MRD) by real-time quantitative reverse transcription PCR (RQ-RT-PCR) in childhood acute myeloid leukemia with AML1/ETO rearrangement
    S Viehmann
    A Teigler-Schlegel
    J Bruch
    C Langebrake
    D Reinhardt
    J Harbott
    Leukemia, 2003, 17 : 1130 - 1136
  • [29] Monitoring of minimal residual disease (MRD) by real-time quantitative reverse transcription PCR (RQ-RT-PCR) in childhood acute myeloid leukemia with AML1/ETO rearrangement
    Viehmann, S
    Teigler-Schlegel, A
    Bruch, J
    Langebrake, C
    Reinhardt, D
    Harbott, J
    LEUKEMIA, 2003, 17 (06) : 1130 - 1136
  • [30] NPM1 Type A mutations as minimal residual disease marker in acute myeloid leukemia patients before allogeneic stem cell transplantation determined by highly sensitive and specific digital droplet PCR is a strong prognosticator for outcome
    Bill, M.
    Kloss, L.
    Jentzsch, M.
    Grimm, J.
    Schubert, K.
    Schulz, J.
    Knyrim, M.
    Cross, M.
    Vucinic, V.
    Behre, G.
    Poenisch, W.
    Franke, G. -N
    Niederwieser, D.
    Schwind, S.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 140 - 140
1234